All posts by: Michael Zand

About Michael Zand

Stemedica: Worldwide License for Stem Cell Stabilization Technologies – Drug Discovery & Development

Continue reading

2015-03-26 NEWS

Stemedica: Worldwide License for Stem Cell Stabilization Technologies
Drug Discovery & Development
“UST’s technology immediately accelerates Stemedica’s development of a wide range of products containing stem cell factors for consumer and medical markets worldwide,” said Nikolai Tankovich, MD, PhD, Stemedica’s President and Chief Medical Officer.

Continue reading

2015-03-26 NEWS

Stemedica: Worldwide License for Stem Cell Stabilization Technologies
Drug Discovery & Development
“UST’s technology immediately accelerates Stemedica’s development of a wide range of products containing stem cell factors for consumer and medical markets worldwide,” said Nikolai Tankovich, MD, PhD, Stemedica’s President and Chief Medical Officer.

Continue reading

2015-03-26 NEWS

MedCity News

AmnioChor is innovating perinatal stem cell technology and the banking industry
MedCity News
What makes AmnioChor’s technology different is the process of freezing a whole piece of the amnion placental tissue, which contains the Mesenchymal and Epithelial stem cells. This approach would provide many more opportunities to use the cells, and …

Continue reading

2015-03-26 NEWS

On stem cell therapy, benefits
Sun.Star
THERE is a lot of hype going on in some circles about stem cell therapy: Is it a cure-all? Is it the elusive fountain of youth? Wikipedia defines stem cell therapy as the “use of stem cells to treat or prevent a disease or condition.” The process

Continue reading

2015-03-26 NEWS

Scientists coax stem cells to form 3D ‘mini-lungs’
Futurity: Research News
Three-dimensional “mini-lungs” coaxed from stem cells and grown in a dish may offer insight into lung disease and could lead to the development of new drugs, scientists say. Previous research has focused on deriving lung tissue from flat cell systems

Continue reading

2015-03-26 NEWS

The Canberra Times

No stem cell treatment for public servant’s dodgy knee
The Canberra Times
A federal public servant has lost a legal bid to have taxpayers pay for experimental stem cell treatment on his dodgy knees. The Administrative Appeals Tribunal has knocked back an appeal by Customs officer Vic Kaplicas to force insurer Comcare to pay …

and more »